Syntheses, Structural Snapshots, Solution Redox Properties, and Cytotoxic Performances of Designated Ferrocene Scaffolds Appended with Organostannyl(IV) benzoates en Route for Human Hepatic Carcinoma
作者:Tushar S. Basu Baul、Dhrubajyoti Dutta、Andrew Duthie、Bruno G. M. Rocha、M. Fátima C. Guedes da Silva、Shashank Saurav、Sunil K. Manna
DOI:10.1021/acs.organomet.8b00278
日期:2018.9.24
heterobimetallic compounds 2, 3, 5–7, and 10 have been determined by X-ray crystallography. The redox properties of FcLnH and their compounds 1–10 were also investigated by cyclic voltammetry. In vitro cytotoxic activities of compounds 1–4, 8, and 9 were assessed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay against human hepatic carcinoma (HepG2) cells, with IC50 values revealing
尽管已经建立了几种策略来规避铂基化学疗法的局限性,但基本问题仍然存在。为此目的,新的系列的异制剂[FCL的Ñ SnPh 3 ](1,3和9)],[FCL Ñ SnBu 3 ] Ñ(2,4和8),[FCL 3 SnCy 3 ](10)和[FcL 3 SnR 3(MeOH)](R = Me(5),Et(6)或Pr(7)),其中FcLn( n = 1-3)表示异构体2- / 3- / 4-二茂铁苯甲酸酯,其合成可以靶向癌细胞,并在化学疗法中连续支持功能性铁缺乏症。化合物1 - 10已经通过元素分析,并且使用IR,NMR,电子和荧光技术的光谱性质进行了研究。金属的分子结构前配体FCL 1 H和FCL 3 H和六个异核化合物2, 3, 5 - 7,和10已经通过X射线晶体学确定。FcL n的氧化还原性质H和它们的化合物1 - 10还通过循环伏安法研究。在化合物的体外细胞毒性活性1 - 4,8,和9,